| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $2,071,145 | 14 | 100 |
Sells | $0 | 0 | 0 |
| Mosseri Marlio Charles | 10 percent owner | 11 | $1.9M | 0 | $0 | $1.9M |
| Sanchez Juan | director | 1 | $75,270 | 0 | $0 | $75,270 |
| Kaplan Matthew L. | director | 1 | $64,240 | 0 | $0 | $64,240 |
| BENTSUR RON | Chairman & CEO | 1 | $28,600 | 0 | $0 | $28,600 |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Over the last 12 months, insiders at Nuvectis Pharma, Inc. have bought $2.07M and sold $0 worth of Nuvectis Pharma, Inc. stock.
On average, over the past 5 years, insiders at Nuvectis Pharma, Inc. have bought $2.17M and sold $22,478 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mosseri Marlio Charles (10 percent owner) — $1.9M. Sanchez Juan (director) — $75,270. Kaplan Matthew L. (director) — $64,240.
The last purchase of 5,000 shares for transaction amount of $28,600 was made by BENTSUR RON (Chairman & CEO) on 2025‑11‑05.
| 2025-11-05 | BENTSUR RON | Chairman & CEO | 5,000 0.0167% | $5.72 | $28,600 | +37.17% | ||
| 2025-11-05 | Kaplan Matthew L. | director | 11,000 0.0376% | $5.84 | $64,240 | +37.17% | ||
| 2025-11-05 | Sanchez Juan | director | 13,000 0.0441% | $5.79 | $75,270 | +37.17% | ||
| 2025-10-27 | Mosseri Marlio Charles | 10 percent owner | 72,836 0.299% | $6.28 | $457,410 | +17.25% | ||
| 2025-10-24 | Mosseri Marlio Charles | 10 percent owner | 35,034 0.1408% | $6.15 | $215,459 | +23.87% | ||
| 2025-10-23 | Mosseri Marlio Charles | 10 percent owner | 46,900 0.1858% | $6.06 | $284,214 | +27.54% | ||
| 2025-06-20 | Mosseri Marlio Charles | 10 percent owner | 5,603 0.0264% | $7.99 | $44,768 | -16.97% | ||
| 2025-06-18 | Mosseri Marlio Charles | 10 percent owner | 28,043 0.1342% | $8.05 | $225,746 | -16.02% | ||
| 2025-06-17 | Mosseri Marlio Charles | 10 percent owner | 5,399 0.0258% | $8.11 | $43,786 | -16.52% | ||
| 2025-05-12 | Mosseri Marlio Charles | 10 percent owner | 21,167 0.0866% | $8.11 | $171,664 | -10.67% | ||
| 2025-05-09 | Mosseri Marlio Charles | 10 percent owner | 25,062 0.1054% | $8.94 | $223,965 | -16.35% | ||
| 2025-05-08 | Mosseri Marlio Charles | 10 percent owner | 2,600 0.0107% | $8.96 | $23,298 | -18.33% | ||
| 2025-05-07 | Mosseri Marlio Charles | 10 percent owner | 12,317 0.0516% | $8.59 | $105,770 | -13.93% | ||
| 2025-05-06 | Mosseri Marlio Charles | 10 percent owner | 12,444 0.051% | $8.59 | $106,955 | -15.79% | ||
| 2025-02-07 | Mosseri Marlio Charles | 10 percent owner | 240,000 0.8579% | $5.00 | $1.2M | +13.79% | ||
| 2024-12-24 | BENTSUR RON | Chairman & CEO | 4,500 0.0233% | $4.65 | $20,925 | +48.71% | ||
| 2024-12-13 | Mosseri Marlio Charles | 10 percent owner | 17,000 0.0872% | $4.70 | $79,900 | +44.68% | ||
| 2024-12-12 | Mosseri Marlio Charles | 10 percent owner | 32,121 0.1662% | $4.64 | $149,041 | +46.23% | ||
| 2024-11-19 | Poradosu Enrique | Chief Science & Business Off | 2,000 0.0103% | $4.99 | $9,980 | +30.74% | ||
| 2024-11-15 | BENTSUR RON | Chairman & CEO | 20,000 0.0887% | $4.92 | $98,400 | +35.96% |
| BENTSUR RON | Chairman & CEO | 3525924 13.3095% | $31.45M | 56 | 0 | <0.0001% |
| Mosseri Marlio Charles | 10 percent owner | 3136576 11.8398% | $27.98M | 33 | 0 | <0.0001% |
| Kaplan Matthew L. | director | 124760 0.4709% | $1.11M | 2 | 0 | <0.0001% |
| Sanchez Juan | director | 78150 0.295% | $697,098.00 | 1 | 0 | |
| Poradosu Enrique | Chief Science & Business Off | 1506319 5.686% | $13.44M | 6 | 0 | +27.24% |
| Shemesh Shay | Chief Dev. & Ops. Officer | 1493068 5.636% | $13.32M | 13 | 0 | +28.02% |
| Carson Michael J. | Vice President, Finance | 87918 0.3319% | $784,228.56 | 0 | 1 | |
| Hoberman Kenneth | 55140 0.2081% | $491,848.80 | 1 | 0 | <0.0001% |
Nuvectis Pharma, Inc. (NVCT) | $8,708,580 | 93 | -5.38% | $236.31M |
$79,019,806 | 27 | 7.24% | $259.34M | |
$22,017,898 | 24 | 39.19% | $239.56M | |
$1,842,003 | 22 | -0.74% | $266.93M | |
$6,915,275 | 21 | -32.61% | $252.76M | |
$110,580 | 16 | 14.52% | $257.1M | |
$245,302 | 15 | -4.08% | $214.08M | |
$4,701,608 | 14 | -4.34% | $240.06M | |
$1,037,470 | 13 | 78.00% | $210.27M | |
$170,425 | 10 | -16.01% | $216.82M | |
$119,804,612 | 8 | -17.22% | $191.61M | |
$145,296,407 | 8 | -0.98% | $189.6M | |
$8,286,963 | 6 | 3.09% | $239.13M | |
$272,982 | 6 | -28.53% | $225.71M | |
$6,049,986 | 4 | -8.38% | $210.26M | |
$1,516,110 | 3 | 8.05% | $236.64M | |
$32,289,200 | 3 | -5.46% | $215.03M | |
$16,003,671 | 3 | 55.38% | $194.6M | |
$37,067 | 3 | -89.81% | $253.31M |
| Increased Positions | 30 | +68.18% | 750,695 | +20.48% |
| Decreased Positions | 17 | -38.64% | 178,284 | -4.86% |
| New Positions | 6 | New | 37,655 | New |
| Sold Out Positions | 7 | Sold Out | 134,502 | Sold Out |
| Total Postitions | 57 | +29.55% | 4M | +15.62% |
| Vanguard Group Inc | $5,946.00 | 2.69% | 698,708 | +31,903 | +4.78% | 2025-09-30 |
| Blackrock, Inc. | $5,832.00 | 2.64% | 685,337 | +42,355 | +6.59% | 2025-09-30 |
| Iridian Asset Management Llc/Ct | $3,452.00 | 1.56% | 405,621 | +32,904 | +8.83% | 2025-09-30 |
| Baldwin Wealth Partners Llc/Ma | $2,982.00 | 1.35% | 350,461 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $2,772.00 | 1.25% | 325,733 | +40,401 | +14.16% | 2025-09-30 |
| Occam Crest Management Lp | $2,468.00 | 1.12% | 290,000 | +290,000 | New | 2025-09-30 |
| State Street Corp | $1,163.00 | 0.53% | 136,716 | +23,137 | +20.37% | 2025-09-30 |
| Northern Trust Corp | $908.00 | 0.41% | 106,641 | -3,176 | -2.89% | 2025-09-30 |
| Susquehanna International Group, Llp | $773.00 | 0.35% | 90,879 | +45,605 | +100.73% | 2025-09-30 |
| Oppenheimer & Co Inc | $588.00 | 0.27% | 69,066 | 0 | 0% | 2025-09-30 |